scFv-ELP Nanoparticles Target CD20+ Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Non-Hodgkin Lymphoma (NHL) often result in severe side effects and resistance, with a need for therapeutics that are less toxic and more effective in targeting CD20+ cells while minimizing harm to healthy tissues.
Innovation Solution
Development of recombinant scFv-ELP polypeptides that self-assemble into nanoparticles, specifically targeting CD20+ cells by fusing an elastin-like peptide (ELP) with a single-chain variable fragment (scFv) of an anti-CD20 antibody, inducing apoptosis and overcoming drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy regimens (CHOP) are used to treat NHL, then treatment effectiveness is achieved in 90% of patients, but severe side effects and cytotoxicity to healthy tissue occur
Solution Approach 1:
The patent segments the therapeutic approach by separating the cytotoxic agent from healthy tissues through targeted delivery. The scFv-ELP nanoparticle system delivers doxorubicin specifically to CD20+ malignant B-cells, isolating the harmful effects to only the target cells while sparing healthy tissue. This segmentation resolves the contradiction by maintaining treatment effectiveness while eliminating systemic cytotoxicity.
Solution Approach 2:
The scFv-ELP nanoparticle acts as an intermediary carrier that selectively transports the cytotoxic drug doxorubicin to the target cells. This intermediary system enables the drug to reach malignant B-cells without exposing healthy tissues to the harmful effects, thus resolving the contradiction between treatment effectiveness and reduction of cytotoxicity to healthy tissue.
2Reliability
If multivalent antibodies against CD20 are used to induce apoptosis, then potency is increased and resistance is overcome, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent merges multiple functions into a single nanoparticle system: the scFv provides CD20 targeting, the ELP provides self-assembly and multivalency, and the encapsulated doxorubicin provides cytotoxic activity. This merging achieves potent apoptosis induction through multivalent binding while avoiding the complexity of assembling multiple separate antibody components, thus resolving the contradiction between potency and manufacturing complexity.
Solution Approach 2:
The patent changes the physical-chemical parameters of the therapeutic system by using ELP's temperature-responsive self-assembly properties to create multivalent nanoparticles. By controlling the self-assembly parameters, the system achieves high potency through multivalent binding while maintaining relatively simple manufacturing processes, resolving the contradiction between apoptosis induction potency and device complexity.
3Object-affected harmful factors
If recombinant scFv-ELP polypeptides are developed to target CD20+ cells specifically, then toxicity to healthy tissue is reduced, but manufacturing precision and purification difficulty increase
Solution Approach 1:
The ELP component provides self-service functionality through its inherent self-assembly properties and temperature-responsive phase transition. This self-assembly behavior enables automatic purification and concentration of the scFv-ELP polypeptide, reducing the need for complex purification steps while maintaining high manufacturing precision. The system essentially purifies itself through controlled self-assembly, resolving the contradiction between reduced toxicity and manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-ELP nanoparticles effectively target and induce apoptosis in CD20+ cells, reducing tumor burden and enhancing survival with reduced toxicity compared to traditional therapies, demonstrating improved efficacy and safety.
Implementation Method 1
recombinant polypeptides comprising, or alternatively consisting essentially of, or yet further consisting of an elastin-like peptide (ELP) and a scFv
Implementation Method 2
ELP-mediated phase separation
Implementation Method 3
the scFv component of the ELP is the single chain variable region from the anti-CD20 antibody
Data Source
AI summary
Disclosed herein are recombinant polypeptides comprising an elastin-like peptide (ELP) and a scFv, or a biological equivalent of the scFv. Also disclosed are compositions containing scFv-ELP polypeptides and methods of use.